English version - This handbook sets out a the new paradigm for pharmacy practice. Its aim is to guide pharmacy educators in pharmacy practice, to educate pharmacy students and to guide pharmacists in practice to update their skills. The handbook, which brings together practical tools and knowledge,... has been written in response to a need to define, develop and generate global understanding of pharmaceutical care at all levels.
more
Spanish version of "Developing Pharmacy Practice" - WHO/FIP Joint handbook -
Este manual de introducción marca un nuevo paradigma en la práctica de farmacia. Intenta guiar a los formadores en atención farmacéutica para educar a los estudiantes de farmacia y a los farmacéuticos ya estableci...dos en la actualización de sus conocimientos. Este manual, que ofrece teoría y ejemplos prácticos, ha sido escrito como respuesta a la necesidad de definir, desarrollar y agrupar todos los conocimientos actuales sobre la atención farmacéutica.
more
The aim of this study is to research deeply on the post-traumatic stress disorder in sexually abused children. Proving the presence of forms of the disorder in children and the their treatment mode will be in the center of the study. The methods used to conduct this study will be a literature review... on the focused issue referring to reviews of articles which focus on the defined peer group. For the purpose we have selected only articles focusing on sexually abused children treated for post-traumatic stress disorder. The results of the study reveal that all forms of abuse could bring consequences on children, even more, posttraumatic stress is the language with which the victims communicate their sorrow in the most typical mode. Sexual abuse as one of the major forms of abuse, is among the most severe which cause irreversible consequences over a category of children. In conclusion we can assume that post-traumatic stress in sexually abused children might appear through the most severe forms of psychiatric and psychological symptoms and for the recovery and rehabilitation of the child in many cases the pharmacological treatment seems as the best choice for the child.
more
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by non-specialists in low and middle income settings? Fo...r prophylaxis to prevent recurrence of simple or complex febrile seizures, which of the pharmacological interventions when compared with placebo/comparator produce benefit/harm in specified outcomes?
- continuous anticonvulsant therapy - intermittent anticonvulsant therapy - intermittent antipyretic treatment
more
Overview
Learning objectives
• Name the general principles of essential care and practice.
• Name management principles of priority MNS conditions.
• Use effective communication skills in interactions with people with MNS conditions.
• Perform assessments for priority MNS conditions.
... Assess and manage physical health in MNS conditions.
• Know the impact of violence and gender-based violence on mental health.
• Provide psychosocial interventions to a person with a priority MNS condition and their
carer.
• Deliver pharmacological interventions as needed and appropriate in priority MNS
conditions considering special populations.
• Plan and perform follow-up for MNS conditions.
• Refer to specialists and links with outside agencies for MNS conditions as appropriate and
available.
• Promote respect and dignity for people with priority MNS conditions.
more
Overview
Learning objectives
• Promote respect and dignity for children and adolescents with mental and behavioural
disorders.
• Know common presentations of children and adolescents with mental and behavioural
disorders.
• Know assessment principles of child and adolescents with mental ...and behavioural
disorders.
• Know management principles of child and adolescents with mental and behavioural
disorders.
• Use effective communication skills in interactions with children and adolescents with
mental and behavioural disorders.
• Perform an assessment for children and adolescents with mental and behavioural
disorders.
• Assess and manage physical conditions of children with mental and behavioural
disorders.
• Provide psychosocial interventions to children and adolescents with mental and
behavioural disorders and their carers.
• Deliver pharmacological interventions as needed and appropriate to children and
adolescents with mental and behavioural disorders.
• Plan and perform follow-up for children and adolescents with mental and behavioural
disorders.
• Refer to specialists and link children and adolescents with mental and behavioural
disorders with outside agencies where available.
more
Overview
Learning objectives
• Promote respect and dignity for people with other significant mental health complaints.
• Know the common presentation of other significant mental health complaints.
• Know the assessment principles of other significant mental health complaints.
• Know the... management principles of other significant mental health complaints.
• Perform an assessment for other significant mental health complaints.
• Use effective communication skills in interaction with people with other significant
mental health complaints.
• Assess and manage physical health in other significant mental health complaints.
• Provide psychosocial interventions to persons with other significant mental health
complaints and their carers.
• Know there are no specific pharmacological interventions for other significant mental
health complaints.
• Plan and perform follow-up for other significant mental health complaints.
• Refer to specialists and links with outside services for other significant mental health
complaints where appropriate and available.
more
Overview
Learning objectives
• Promote respect and dignity for people with psychoses.
• Name common presentations of psychoses.
• Name assessment principles of psychoses.
• Name management principles of psychoses.
• Perform an assessment for psychoses.
• Use effective communicatio...n skills when interacting with a person psychoses.
• Assess and manage physical health concerns in psychoses.
• Assess and manage emergency presentations of psychoses.
• Provide psychosocial interventions to persons with psychoses and their carers.
• Deliver pharmacological interventions as needed and appropriate in psychoses
considering special populations.
• Plan and performs follow-up sessions for people with psychoses.
• Refer to specialist and links with outside agencies for psychoses as appropriate and
available.
more
Information on 102 commonly used medicinal plants in the South Pacific WHO regional publications. Western Pacific series ; Plants from this part of the world represent an especially diverse flora and include several species currently undergoing scientific investigation. Common traditional uses inclu...de the treatment of minor injuries, childhood ailments, and complications of pregnancy. Plants described in the book are also used as emetics and as ointments and dressings applied to surface wounds or used to treat skin problems.
Addressed to ethnobotanists, phytochemists, and pharmacologists, the book aims to document traditional clinical uses and bring these to the attention of the international scientific community, while also preserving knowledge about the distinctive indigenous practices in these island communities. Full-colour photographs are included to facilitate identification of plants and plant parts used for medicinal purposes. Each plant is described according to a common format, which includes information on scientific name, local names, English name, a description of the plant and its habitat and distribution, and a summary of what is known about its chemical constituents, biological activity, and traditional uses.
more
BUKO Pharma-Kampagne has investigated the causes and consequences of antibiotic resistance in India, South Africa, Tanzania and Germany. Together with our partners we collected data and did interviews with numerous stakeholders. The outcome is presented in a brochure that is now available in English...
Resistant bacteria are spreading worldwide. In collaboration with partners in India, Tanzania, South Africa and Germany, we have investigated the causes and consequences of this spread.2 This Pharma-Brief Special presents the results. It examines the risks for humans, animals and the environment. It focuses on local problems and approaches, international interactions and the re-sponsibility of doctors, farmers and consumers.
more
This publication provides recommendations for the management of critically ill adult patients with COVID-19 being treated in intensive care units (ICUs) in the Americas. These clinical practice guidelines provide evidence-informed recommendations for identifying markers and mortality risk factors in... critically ill patients, as well as infection control, sample collection, supportive care (respiratory and hemodynamic), pharmacological treatment, early rehabilitation, diagnostic imaging use, prevention of complications, and discharge requirements. The recommendations are for all health care staff caring for patients in emergency departments and ICUs. These guidelines are also intended for use by decisionmakers and government entities involved in the management of patients with COVID-19 in ICUs in the Region of the Americas.
more
Accessed on 15.08.2022
La farmacovigilancia es una herramienta que permite la detección, evaluación, conocimiento y prevención de efectos adversos y/o inesperados de los medicamentos que se prescriben. También facilita la detección de fallas de respuesta terapéutica por deficiencias de calid...ad.
more
Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv...oir of the infections. There is a strong need to control AAT, as is claimed by the European Commission in a recent document on the reservation of antimicrobials for human use. Control of AAT is considered part of the One Health approach established by the FAO program against African Trypanosomiasis. Under the umbrella of the One Health concepts, in this work, by analyzing the pharmacological properties of the therapeutic options against Trypanosoma brucei spp., we underline the need for clearer and more defined guidelines in the employment of drugs designed for HAT and AAT. Essential requirements are addressed to meet the challenge of drug use and drug resistance development. This approach shall avoid inter-species cross-resistance phenomena and retain drugs therapeutic activity.
more
Chagas heart disease (CHD) affects approximately 30% of patients chronically infected with the protozoa Trypanosoma cruzi. CHD is classified into four stages of increasing severity according to electrocardiographic, echocardiographic, and clinical criteria. CHD presents with a myriad of clinical man...ifestations, but its main complications are sudden cardiac death, heart failure, and stroke. Importantly, CHD has a higher incidence of sudden cardiac death and stroke than most other cardiopathies, and patients with CHD complicated by heart failure have a higher mortality than patients with heart failure caused by other etiologies. Among patients with CHD, approximately 90% of deaths can be attributed to complications of Chagas disease. Sudden cardiac death is the most common cause of death (55%-60%), followed by heart failure (25%-30%) and stroke (10%-15%). The high morbimortality and the unique characteristics of CHD demand an individualized approach according to the stage of the disease and associated complications the patient presents with. Therefore, the management of CHD is challenging, and in this review, we present the most updated available data to help clinicians and cardiologists in the care of these patients. We describe the clinical manifestations, diagnosis and classification criteria, risk stratification, and approach to the different clinical aspects of CHD using diagnostic tools and pharmacological and non-pharmacological treatments.
more
A century after its discovery, Chagas' disease still represents a major public health challenge in Latin America. Moreover, because of growing population movements, an increasing number of cases of imported Chagas' disease have now been detected in non-endemic areas, such as North America and some E...uropean countries. This parasitic zoonosis, caused by Trypanosoma cruzi, is transmitted to humans by infected Triatominae insects, or occasionally by non-vectorial mechanisms, such as blood transfusion, mother to fetus, or oral ingestion of materials contaminated with parasites. Following the acute phase of the infection, untreated individuals enter a chronic phase that is initially asymptomatic or clinically unapparent. Usually, a few decades later, 40-50% of patients develop progressive cardiomyopathy and/or motility disturbances of the oesophagus and colon. In the last decades several interventions targeting primary, secondary and tertiary prevention of Chagas' disease have been attempted. While control of both vectorial and blood transfusion transmission of T cruzi (primary prevention) has been successful in many regions of Latin America, early detection and aetiological treatment of asymptomatic subjects with Chagas' disease (secondary prevention) have been largely underutilised. At the same time, in patients with established chronic disease, several pharmacological and non-pharmacological interventions are currently available and have been increasingly used with the intention of preventing or delaying complications of the disease (tertiary prevention). In this review we discuss in detail each of these issues.
more
The Pharmaceutical Forum of the Americas (PFA) has previously published guidelines and organised campaigns for community pharmacists on the prevention, detection and control of arbovirus infections in 2018 with a grant from the FIP Foundation for Pharmacy Education and Research. Building on that exp...ertise, FIP joined efforts with the PFA and is now publishing its first-ever handbook to support pharmacists in the
area of vector-borne diseases. As the integration of the regional forums in FIP advances, such collaborative projects are tangible results of an increasingly regionally informed and regionally targeted work by FIP.
more
Approximately 80% of the 463 million adults worldwide with diabetes live in low-income and middle-income countries (LMICs). A major obstacle to designing evidence-based policies to improve diabetes outcomes in LMICs is the scarce availability of nationally representative data on the current patterns... of treatment coverage. The objectives of this study were to estimate the proportion of adults with diabetes in LMICs who receive coverage of recommended pharmacological and non-pharmacological diabetes treatment; and to describe country-level and individual-level characteristics that are associated with treatment.
more
Approximately 80% of the 463 million adults worldwide with diabetes live in low-income and middle-income countries (LMICs). A major obstacle to designing evidence-based policies to improve diabetes outcomes in LMICs is the scarce availability of nationally representative data on the current patterns... of treatment coverage. The objectives of this study were to estimate the proportion of adults with diabetes in LMICs who receive coverage of recommended pharmacological and non-pharmacological diabetes treatment; and to describe country-level and individual-level characteristics that are associated with treatment.
more